Pfizer Vaccine Disappoints in Children Ages 2 to 5 Years

Pfizer-BioNTech will try a third dose to see if it produces a more robust response

child vaccine
Adobe Stock

FRIDAY, Dec. 17, 2021 (HealthDay News) -- Two doses of a pediatric Pfizer-BioNTech COVID-19 vaccine failed to spur an adequate immune response in children ages 2 to 5 years, the companies announced Friday.

The pediatric trials used a 3-µg dose of the vaccine -- equivalent to about one-tenth of the dose used in adult shots. And while two 3-µg doses produced a good immune response in babies and children between 6 months and 2 years of age -- similar to that seen in people ages 16 to 25 years -- they failed to do so in the 2- to 5-year age group, the companies said in a statement.

Pfizer-BioNTech says they will try a third dose to see if that produces a more robust response, but they have no plans to try any amount of vaccine above 3 µg. Children younger than 5 years will get the third dose two months after they have received their second.

There is a building consensus that three doses of vaccine, not two, offers the best defense against COVID-19, including newer variants such as omicron.

Besides the ongoing trials in very young children, Pfizer-BioNTech is also conducting trials of three doses of 10 µg of COVID-19 vaccine (one-third of the dosage used in adults) in children ages 5 through 12 years, the companies said. They hope to complete the trials and ask for U.S. Food and Drug Administration authorization of a three-dose vaccine series in younger children sometime in the spring of 2022.

More Information

Physician’s Briefing Staff

Physician’s Briefing Staff

Published on December 17, 2021

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ